THE European Medicine Agency’s
Committee for Medicinal Products
for Human Use has recommended
the approval of a marketing
authorisation for Nuedexta
(dextromethorphan/quinidine) for
the treatment of Pseudobulbar
Affect (PBA) - a medical condition
where patients experience sudden
and uncontrollable bouts of
laughing or crying disproportionate
to their emotional state.
It occurs when certain medical
disorders, such as MS and
amyotrophic lateral sclerosis or a
stroke, damage certain brain areas.
The EMA has also recommended
approval of matrix-induced
autologous chondrocyte
implantation (MACI), and
advanced-therapy medicinal
product for the repair of fullthickness
knee cartilage defects in
adult patients.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Apr 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.